TORRENT PHARMACEUTICALS L vs WINDLAS BIOTECH LIMITED
A side-by-side comparison of TORRENT PHARMACEUTICALS L (TORNTPHARM) and WINDLAS BIOTECH LIMITED (WINDLAS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads TORNTPHARM vs WINDLAS on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability31
- Growth11
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
TORNTPHARM takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 19.8%", "Promoter holding has increased by 1.41% over last quarter.", "Company's working capital requirements have reduced from 21.4 days to 14.4 days"]
- − ["Company has a low return on equity of 12.8% over last 3 years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.